Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP5 | P45974 | 1/20 | 0.72 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HSD17B3 | P37058 | 7/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1114978 | 0.93 | USP5 (0.80) | USP5NPC1RAB9APOLBMEN1 | |
| SCHEMBL30089581 | 0.91 | USP5 (0.85) | USP5NPC1RAB9APOLBMEN1 | |
| SCHEMBL1115053 | 0.91 | USP5 (0.77) | USP5NPC1RAB9APOLBMEN1 | |
| SCHEMBL5566974 | 0.90 | USP5 (0.66) | USP5NPC1RAB9APOLBMEN1 | |
| SCHEMBL1115055 | 0.89 | USP5 (0.60) | USP5NPC1RAB9APOLBMEN1 | |
| SCHEMBL30871980 | 0.89 | HSD17B3 (0.66) | USP5HSD17B3L3MBTL1HTR7 | |
| SCHEMBL11834369 | 0.89 | USP5 (0.64) | USP5NPC1RAB9APOLBMEN1 | |
| SCHEMBL2923903 | 0.89 | USP5 (0.64) | USP5NPC1RAB9APOLBMEN1 | |
| SCHEMBL11290691 | 0.89 | USP5 (0.64) | USP5NPC1RAB9APOLBMEN1 | |
| SCHEMBL27841966 | 0.89 | USP5 (0.64) | USP5NPC1RAB9APOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423059-B2 | Pharmaceutically active compounds and methods of use | WYETH (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423059-B2 | Pharmaceutically active compounds and methods of use | WYETH (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423059-B2 | Pharmaceutically active compounds and methods of use | WYETH (US) | 2008-09-09 | — | — | US | disclosed |
| US-20050209222-A1 | Pharmaceutically active compounds and methods of use | CAMBRIDGE NEUROSCIENCE, INC. | 2005-09-22 | — | — | US | disclosed |
| US-6756389-B2 | CENTRAL NERVOUS SYSTEM DISORDERS | CAMBRIDGE NEUROSCIENCE, INC. | 2004-06-29 | — | — | US | disclosed |
| US-20030069274-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | WYETH | 2003-04-10 | — | — | US | disclosed |
| EP-0959887-A4 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE INC (US) | 2003-01-08 | — | — | EP | disclosed |
| EP-0959887-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-12-01 | — | — | EP | disclosed |
| WO-1998006401-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1998-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209222-A1 | Pharmaceutically active compounds and methods of use | ACHE, NLN, PARK7 | USP5 2613/4885NPC1 75/4885RAB9A 1933/4885 |
| US-20030069274-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | ACHE, NLN, PARK7 | USP5 2613/4885NPC1 75/4885RAB9A 1933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.